Ensifentrine

DRUG5 trials

Sponsors

Verona Pharma plc, Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Nuance Pharma (shanghai) Co., Ltd

Conditions

COPDChronic Obstructive Pulmonary Disease

Phase 1

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects

CompletedNCT05758428

Nuance Pharma (shanghai) Co., LtdChronic Obstructive Pulmonary Disease

Start: 2023-03-06End: 2023-04-18Updated: 2023-04-24

Phase 2

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

RecruitingNCT05270525

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USACOPD

Start: 2022-05-27End: 2027-06-01Target: 56Updated: 2026-05-13

Phase 3

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

CompletedNCT04535986

Verona Pharma plcChronic Obstructive Pulmonary Disease

Start: 2020-09-29End: 2022-12-02Updated: 2023-11-13

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

CompletedNCT04542057

Verona Pharma plcChronic Obstructive Pulmonary Disease

Start: 2020-09-22End: 2022-07-06Updated: 2023-10-16

A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

CompletedNCT05743075

Nuance Pharma (shanghai) Co., LtdChronic Obstructive Pulmonary Disease

Start: 2023-03-10End: 2025-03-07Updated: 2025-06-04

Related Papers

Lung Function and Safety Outcomes in Patients With Moderate-to-Severe COPD Treated With Ensifentrine

CHEST Pulmonary2025-09-02

Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies

Chronic Respiratory Disease2025-01-2412 citations

Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD.

2024-08-2711 citations

Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials

Expert Review of Respiratory Medicine2024-08-0210 citations

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

American Journal of Respiratory and Critical Care Medicine2023-06-26116 citations